Trials / Completed
CompletedNCT00694187
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to show the bioequivalence of a Roxane Laboratories' Zaleplon Capsules, 10 mg, to Sonata ® Capsules, 10 mg (Jones Pharma) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zaleplon |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2008-06-10
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00694187. Inclusion in this directory is not an endorsement.